EA201791500A1 - Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости - Google Patents

Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости

Info

Publication number
EA201791500A1
EA201791500A1 EA201791500A EA201791500A EA201791500A1 EA 201791500 A1 EA201791500 A1 EA 201791500A1 EA 201791500 A EA201791500 A EA 201791500A EA 201791500 A EA201791500 A EA 201791500A EA 201791500 A1 EA201791500 A1 EA 201791500A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modulators
mucoviscidous
cyclopropankarcarboxamid
regulator
transmembrane conductor
Prior art date
Application number
EA201791500A
Other languages
English (en)
Inventor
Чэнчжи Чжан
Джастин Чакма
Original Assignee
Оспекс Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оспекс Фармасьютикалз, Инк. filed Critical Оспекс Фармасьютикалз, Инк.
Publication of EA201791500A1 publication Critical patent/EA201791500A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение относится к новым циклопропанкарбоксамидным модуляторам белков муковисцидозного трансмембранного регулятора проводимости, их фармацевтическим композициям и способам их применения.
EA201791500A 2014-12-31 2015-12-27 Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости EA201791500A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098735P 2014-12-31 2014-12-31
PCT/US2015/067544 WO2016109362A1 (en) 2014-12-31 2015-12-27 Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator

Publications (1)

Publication Number Publication Date
EA201791500A1 true EA201791500A1 (ru) 2018-01-31

Family

ID=56284953

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791500A EA201791500A1 (ru) 2014-12-31 2015-12-27 Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости

Country Status (10)

Country Link
US (2) US10167278B2 (ru)
EP (1) EP3240539A4 (ru)
AR (1) AR103355A1 (ru)
AU (1) AU2015374342A1 (ru)
BR (1) BR112017014213A2 (ru)
CA (1) CA2970948A1 (ru)
EA (1) EA201791500A1 (ru)
IL (1) IL252818A0 (ru)
TW (1) TW201625597A (ru)
WO (1) WO2016109362A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX342288B (es) 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
ES2957761T3 (es) 2014-04-15 2024-01-25 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
CN109528634A (zh) * 2018-12-19 2019-03-29 江西润泽药业有限公司 复方克林霉素甲硝唑葡萄糖注射液及其制备方法
CN109633040A (zh) * 2019-02-26 2019-04-16 山东博济医药科技有限公司 一种羧甲司坦含量测定方法
CN110227063B (zh) * 2019-06-18 2021-06-15 石药银湖制药有限公司 一种利奈唑胺注射液的制备方法
CN117643588A (zh) * 2023-11-13 2024-03-05 山东天宏生物医药有限公司 呋喃妥因在制备抗类风湿性关节炎药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645789B2 (en) * 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
UA104876C2 (ru) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модуляторы атф-связывающих кассетных транспортеров
NZ609962A (en) 2008-11-06 2014-11-28 Vertex Pharma Modulators of atp-binding cassette transporters
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8802868B2 (en) * 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2604105T3 (es) 2010-03-25 2017-03-03 Vertex Pharmaceuticals Incorporated Formula cristalina de (r) -1 (2,2- difluorobenzo [d] [1,3] dioxol - 5yl) - n- (1- (2,3 - dihidroxipropil) - 6 - fluoro - 2- (1 - hydroxy-2-metilpropan-2il) -1h-indol-5il) cyclopropanecarboxamida
MX342288B (es) * 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
WO2011133956A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
RU2013112937A (ru) 2010-08-23 2014-09-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции (r)-1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)-n-(2, 3-дигидроксипропил)-6-фтор-2-(1-гидрокси-2-метилпропан-2-ил)-1н-индол-5-ил)циклопропанкарбоксамида и их применение
HUE047354T2 (hu) * 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
IN2014KN00885A (ru) 2011-11-08 2015-10-02 Vertex Pharma
EP2858645A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661

Also Published As

Publication number Publication date
US20180265501A1 (en) 2018-09-20
IL252818A0 (en) 2017-08-31
US10167278B2 (en) 2019-01-01
EP3240539A4 (en) 2018-07-25
BR112017014213A2 (pt) 2018-04-10
US10689370B2 (en) 2020-06-23
AU2015374342A1 (en) 2017-07-20
AR103355A1 (es) 2017-05-03
US20190367492A1 (en) 2019-12-05
WO2016109362A1 (en) 2016-07-07
TW201625597A (zh) 2016-07-16
CA2970948A1 (en) 2016-07-07
EP3240539A1 (en) 2017-11-08

Similar Documents

Publication Publication Date Title
EA201791500A1 (ru) Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201691582A1 (ru) Новые фармацевтические препараты
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201890052A1 (ru) Регуляторы nrf2
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
MX370450B (es) Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
MA44008A (fr) 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b
MX2016016886A (es) Anticuerpos anti-axl.
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
CY1123031T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
EA201890245A1 (ru) Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
EA201791454A1 (ru) Лекарственные формы для трансдермального введения